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Background: The anterior cruciate ligament (ACL) is one of four major ligaments in the knee that provide stability
during physical activity. A tear in the ACL is characterized by joint instability that leads to decreased activity, knee
dysfunction, reduced quality of life and a loss of muscle mass and strength. While rehabilitation is the standard-of-care
for return to daily function, additional surgical reconstruction can provide individuals with an opportunity to return to
sports and strenuous physical activity. Over 200,000 ACL reconstructions are performed in the United States each year,
and rehabilitation following surgery is slow and expensive. One possible method to improve the recovery process is
the use of intramuscular testosterone, which has been shown to increase muscle mass and strength independent of
exercise. With short-term use of supraphysiologic doses of testosterone, we hope to reduce loss of muscle mass and
strength and minimize loss of physical function following ACL reconstruction compared to standard-of-care alone.
Methods/design: This study is a double-blinded randomized control trial. Men 18–50 years of age, scheduled for ACL
reconstruction are randomized into two groups. Participants randomized to the testosterone group receive intramuscular
testosterone administration once per week for 8 weeks starting 2 weeks prior to surgery. Participants randomized to the
control group receive a saline placebo intramuscularly instead of testosterone. Lean mass, muscle strength and physical
function are measured at 5 time points: 2 weeks pre-surgery, 1 day pre-surgery, and 6, 12, 24 weeks post-surgery. Both
groups follow standard-of-care rehabilitation protocol.
Discussion: We believe that testosterone therapy will help reduce the loss of muscle mass and strength experienced
after ACL injury and reconstruction. Hopefully this will provide a way to shorten the rehabilitation necessary following
ACL reconstruction. If successful, testosterone therapy may also be used for other injuries involving trauma and muscle
atrophy.
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The anterior cruciate ligament is one of four major liga-
ments in the knee and provides stability during physical
activity. A tear in the ligament is characterized by joint in-
stability that leads to decreased activity, knee dysfunction,
and reduced quality of life [1]. The initial knee injury is
associated with rapid loss of muscle mass and strength,
which can be regained with structured rehabilitation [1].
While rehabilitation is the standard-of-care for return to
daily function, additional surgical reconstruction can pro-
vide individuals with an opportunity to return to sports
and strenuous physical activity [2]. However, surgery will
initially add more trauma to the knee and prolong
rehabilitation. Together, these components can lead to a
slow and expensive recovery [3]. Because there are at least
200,000 anterior cruciate ligament (ACL) reconstructions
performed each year in the United States [1], it will be
beneficial to improve the recovery process. One possible
method may be the use of intramuscular testosterone,
which has been shown to increase muscle mass and
strength independent of exercise [4,5]. Inducing an ana-
bolic environment with a short course of testosterone may
be an efficient method to improve recovery.
Muscle mass is dependent on the ratio of muscle protein
synthesis (anabolism) to muscle protein breakdown (catab-
olism). Trauma from surgery and limited movement of the
knee result in atrophy and breakdown due to a catabolic
state and reduced anabolism of skeletal muscle proteins.
Furthermore, ACL injuries can result in weeks of immobili-
zation of the knee, and animal studies have shown that
anabolism decreases after as few as 6 hours of cast immo
bilization [6]. The combination of surgery, the initial knee
injury, and the associated limited movement contribute to
the delayed and intensive rehabilitative process.
Testosterone increases myofibrillar protein synthesis and
promotes anabolism of muscle tissue. It also modulates the
activity of immune, fibroblast, and myogenic precursor
cells, which are all involved in muscle regeneration. Fur-
thermore, testosterone administration increases lean tissue
and maximal voluntary strength in a dose-dependent man-
ner [5]. Animal models have shown that exogenous testos-
terone aids in muscle regeneration following several types
of injury, such as crush injuries, venom-induced muscle
injury, muscle disuse atrophy, and injury following muscle
graft surgery [7]. With testosterone, successful regener-
ation of healthy mouse muscle can occur within 2–3 weeks
of injury where muscle strength can return to pre-injured
values [7].
Testosterone may also induce muscle growth via growth
hormone (GH) and insulin-like growth factor 1 (IGF-1)
[7,8]. IGF-1 can stimulate muscle protein synthesis and
satellite cell activity and anabolic steroids increase both
circulating IGF-1 and muscle mRNA expression of IGF-1.
Akt (protein kinase B) is a signaling mediator of IGF-1that can regulate muscle mass. However, it is also known
that testosterone can work outside of the Akt signaling
pathway in order to maintain skeletal muscle hypertrophy
[7,9]. We are studying key regulatory proteins such as
Akt1, mTOR, and FOXO3a, which have not been studied
in concurrent states of muscle trauma and testosterone
administration.
There is evidence that the Akt pathway regulates gene
transcription through the inactivation of a group of tran-
scription factors (FOXOs) located in the nucleus [10,11].
FOXO3a increases the transcription of atrophy related
genes (atrogens), decreases protein degradation, and re-
sults in muscle atrophy. Phosphorylation of FOXO3a by
phosphorylated Akt1 inactivates the transcription factor,
releasing it from DNA and resulting in translocation of
the inactive FOXO3a to the cytosol [11]. Phosphorylated
Akt1 will also activate the mTOR pathway to stimulate
protein synthesis and result in hypertrophy [11]. There-
fore, the Akt pathway may regulate both skeletal muscle
protein synthesis and degradation by different but
complimentary mechanisms in response to testosterone
(Figure 1). By analyzing muscle tissue following an ACL
rupture with or without testosterone administration, we
can learn more about the mechanism through which
muscle adapts to trauma and how testosterone affects this
process. Therefore, we may learn more about testoster-
one’s mechanism of action in skeletal muscle during the
catabolic stimulus of bedrest and surgery.
In addition to understanding the possible mechanisms
of testosterone, there may be improved recovery time as
measured by questionnaires and function tests. In a study
using the Tegner Activity Scale [12], a questionnaire
developed to describe a patient’s physical activity, 60% of
participants who received ACL reconstruction did not
return to pre-injury activity level within 2 years [1]. In an-
other study where supraphysiologic doses of testosterone
were given to older men undergoing knee replacement,
the physical function as measured by the Functional Inde-
pendence Measure ability to stand was significantly higher
by 30% in patients who received testosterone. Similarly,
we hope to improve recovery following ACL reconstruc-
tion using supraphysiologic doses of testosterone. Specific-
ally, we hope to reduce the loss of muscle mass and
strength and minimize loss of physical function. Should
acute testosterone improve rehabilitation following ACL
surgery, it may be possible to apply the same concept to
other injuries that involve muscle atrophy.
Objectives
The overall objective of this study is to determine if
8 weeks of testosterone first administered 2 weeks prior to
surgery, can improve the outcome of ACL reconstruction.
Specifically, we will evaluate the effect of testosterone
administration on lean muscle mass and strength, physical
Figure 1 Akt1 signaling and control of skeletal muscle hypertrophy and atrophy. Anabolic signals (e.g. testosterone) initiate phosphorylation
(P) of Akt1, which activates protein synthesis via the mTOR pathway. At the same time, Akt1(P) inactivates FOXO3a by phosphorylation and facilitates
translocation of FOXO3a out of the nucleus, resulting in inhibition of the atrophy-related genes (atrogens), and thereby decreasing protein degradation.
On the other hand, catabolic stimuli (e.g. glucocorticoids) dephosphorylate and thereby inactivate the Akt1 protein. Inactivation of the Akt1 protein allows
expression of FOXO3a in the nucleus and subsequent activation of the atrogens, resulting in protein degradation. (Figure adapted from G.A. Nader) [10].
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regulators following ACL reconstructive surgery. We
hypothesize that testosterone will minimize the reductions
or potentially increase muscle mass and strength following
surgery and may hasten a patient’s return to physical
activity. If testosterone improves recovery after ACL
surgery, the same treatment may be used for other injuries
that involve trauma and muscle atrophy. Furthermore, this
study will examine the effect of trauma with or without
testosterone on myogenic regulators in muscle tissue
taken during ACL surgery—providing possible mechanis-
tic insights for the clinical outcomes.
Methods
Study design
Men, 18–50 years of age, scheduled for ACL reconstructive
surgery will be randomized to one of two groups. Although
most ACL tears occur in women [2], this study will be lim-
ited to men due to the gender-related side effects of testos-
terone. According to our power analysis, we aim to have at
least 7 patients in each group after recruiting and screening
approximately 70 patients. The dosing is based on a previ-
ous study using supraphysiological dose of testosterone for
knee replacement surgery [13]. Intramuscular testosterone
cypionate will be used because it has been more widely
studied and is less expensive than the gel or patch forms of
testosterone. Group 1 will receive testosterone administra-
tion, one weekly 200 mg dose intramuscularly of testoster-
one in sesame oil, for 8 continuous weeks beginning2 weeks prior to surgery and standard-of-care rehabilita-
tion following surgery. Group 2 will follow the same dosing
and rehabilitation schedule but receive a saline placebo in-
stead of testosterone. The dose will be given intramuscu-
larly to minimize systemic side effects; however, we expect
the total systemic levels of testosterone to increase to an
average of 1200 ng/dl. Lean mass, muscle strength, and
physical function will be measured 2 weeks prior to
surgery, 1 day prior to surgery, and 6, 12, and 24 weeks
following surgery. By administering the dose 2 weeks prior
to surgery, there will be sufficient time to develop an
anabolic state before the catabolic stimulus of surgery. The
dose will continue for 8 weeks to try to maintain muscle
mass when there is limited movement and endogenous
anabolic stimulus. After 6 weeks from the surgery, testos-
terone will no longer be administered because KOOS func-
tion and sports score appear to stabilize after this time [1].
The study will be a double-blinded experiment.
Patients will follow a standard rehabilitation protocol
[14] customized by an orthopedic physician. Rehabilitation
will begin shortly after surgery and will be supervised by a
licensed physical therapist. The protocol includes goals for
range of motion, muscle function, and functional perform-
ance at different post-operative stages. The goals for each
stage must be met before patient progresses to the next
stage and the amount of exercises will be closely moni-
tored by physical therapists and the graduate student. A
quicker progression is expected in patients assigned to
standard-of-care rehabilitation with testosterone. If any
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Eligible participants will have had: • Previous major knee injury or
knee surgery
• A complete ACL tear as visualized
on MRI
• Associated posterior cruciate
ligament (PCL) or medical
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treating clinician.
The study will be conducted at the University of Southern
California (USC), Keck School of Medicine in Los Angeles,
California and was approved by the Institutional Review
Board of the University of California (HS-11-00649).collateral ligament (MCL) injury
grade III
° The ACL injury can be either
“isolated” or combined with one
or several of the following
injuries visualized on MRI and/or
arthroscopy:
• Concomitant severe injury to
contra-lateral knee
▪ A meniscus tear that is either left
untreated or treated with a
partial resection
• Injury to the lateral/posterolateral
ligament complex with
significantly increased laxity
▪ A small, stable meniscus tear
treated with fixation, but with the
fixation not interfering with the
rehabilitation protocol
• Unstable longitudinal meniscus
tear that requires repair and
where the following
postoperative treatment (e.g.
bracing and limited range of
motion) interferes with the
rehabilitation protocol





• A radiographic examination with
normal joint status or combined
with either one of the following
findings:
• Cartilage injury representing a full
thickness loss down to bone
° A small-avulsed fragment located
laterally, usually described as a
Segond fracture, JSN grade 1 or
osteophytes grade 1 as
determined by the OARSI
atlas[15]
• Total rupture of MCL/LCL as
visualized on MRI.
• History of deep vein thrombosis
(DVT) or a disorder of the
coagulative system
• Claustrophobia
• Prior or current use of anabolicSelection and randomization of subjects
Male participants, 18–50 years of age, who present to the
orthopedic surgeon with recent knee trauma will be
screened for eligibility. Eligible patients will have had
rotational trauma to a previously uninjured knee within
the preceding 8 months, ACL insufficiency as determined
by clinical examination (positive pivot shift and/or positive
Lachmann test), and a score of 5 to 9 on the Tegner Activ-
ity Scale (TAS) [12] before the injury (scores range from 1
to 10, with a score of 5 indicating participation in recre-
ation sports, and a score of 9 indicating participation in
competitive sports on a nonprofessional level).
All eligible participants (see Table 1) will receive informa-
tion about the trial orally and in writing. After signing a
written informed consent, they will be randomly assigned
to undergo either standard-of-care structured rehabilitation
with testosterone administration or standard-of-care struc-
tured rehabilitation with placebo. An investigator not
involved in the randomization procedure will prepare
sequentially numbered, opaque, sealed envelopes contain-
ing the assigned interventions to ensure randomness which
will then be provided to the research pharmacist. The study
is a double blind study. Only the research pharmacist will
know which patient is receiving study drug or placebo. The
surgeon, PI, study team, and physical therapist will not
know which study arm the patient was randomized. The
protocol for rehabilitation will remain the same for all
patients.steroids
• General systemic disease affecting
physical function
• Chromosomal disorders
• Medications that interfere with
testosterone production or
function, including but not
limited to 5α-reductase inhibitors
• Any other condition or treatment
interfering with the completion
of the trialStudy agent administration and safety
Although the study involves a very short course of tes-
tosterone, it may still have side effects on the endocrine
systems; and therefore, common markers of endocrine
function are monitored. Blood analysis will be performed
at USC. Pituitary hormones (LH and FSH), prostate-
specific antigen (PSA), liver enzymes, hematocrit, and
blood pressure are measured at two weeks preopera-
tively, 1 day preoperatively, and 2, 3, 6, 12, and 24 weeks
postoperatively.Orthopedic surgery
Surgery will be performed for all eligible patients within
8 months after the injury by a licensed orthopedic surgeon.
Surgery will be performed while the patient is under gen-
eral anesthesia. Meniscal surgery will be carried out asneeded, followed by ACL reconstruction. All surgeons have
similar success rates for ACL reconstruction.
Rehabilitation
Rehabilitation will follow a standard guideline [16] under
the supervision of a licensed physical therapist and the
participant’s doctor.
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During surgery, vastus lateralis muscle tissue will be
obtained. The tissue will then be examined by q-PCR for
changes in the gene expression of Akt-1, mTOR, and
FOXO3a [17-21]. In tissues that have received 2 weeks
of testosterone, we expect to see up-regulated expression
of Akt-1 and mTOR, and down-regulated expression of
FOXO3a. Akt-1 phosphorylation will also be detected by
western blotting, and should be higher in patients re-
ceiving testosterone.
Clinical and laboratory evaluations
The patient will be tested on multiple occasions. All
testing takes place at the USC Clinical Exercise Research
Center (CERC). Information will be collected 2 weeks
prior to surgery, followed by measurements 1 day prior to
surgery, and 2, 6, 12, and 24 weeks after surgery. Surgery
will be performed on an arranged date with the orthopedic
surgeon. Physical therapy will follow a pre-defined proto-
col with a physical therapist.
Table 2 outlines the timeline used for the study including
the dates of each visit and what takes place on each visit.
Drug delivery
Either testosterone or placebo will be injected intramuscu-
larly once per week for 8 weeks, starting 2 weeks prior to
surgery and ending 5 weeks post-surgery.
Blood draw
Blood will be collected to monitor any adverse effects on
the participant’s health.
Body composition testing by bioelectrical impedance
The Biospace InBody 520 [22] device measures body com-
position as the participant stands on a scale-like device
while grasping two handles; one in each hand. The device
works by sending a very low-voltage electrical signalTable 2 Study calendar
Timeline Drug delivery Blood collectio
2 weeks prior to surgery X X
1 week prior to surgery X
1 day prior to surgery X X
1 week post-surgery X
2 weeks post-surgery X X
3 weeks post-surgery X
4 weeks post-surgery X
5 weeks post-surgery X
6 weeks post-surgery X
12 weeks post-surgery X
24 weeks post-surgery X
BC = Body Composition, PF = Physical function.through the body to determine water content, body fat
percentage, and lean (muscle) mass.
Body composition testing by DXA
We will also measure the participant’s lean mass and body
fat percentage by whole-body dual-energy x-ray absorpti-
ometry [22-24] (DXA), which is more sensitive to small
changes in body composition than bioelectrical imped-
ance. The subject will have DXA scans throughout the
study. The DXA works by passing low energy x-rays
through the subject’s body. The x-ray is absorbed differ-
ently by muscle tissue than fat tissue which allows the
device to differentiate the amount of lean mass and fat
mass in the participant’s body.
Physical function tests
At 2 weeks prior to surgery, 1 day prior to surgery, and 6,
12, and 24 weeks after surgery, tests of maximal muscle
strength using a Cybex dynamometer [25-27] will be per-
formed on the subject’s unaffected and affected leg. In
addition, knee stability and flexibility tests of the affected
leg are typically performed during rehabilitation. During
later stages of rehabilitation, tests may include the single
leg squat, single leg hop, X-hop, triple hop, and timed hop
tests [19,28-31].
Questionnaires
The subject will be asked to complete the Knee Injury
and Osteoarthritis Outcome Score [32,33] (KOOS), a
commonly used test to measure progression after ACL
reconstruction, and the Tegner Activity Scale [12,34-37]
to determine physical activity level.
Statistical data analysis
Descriptive statistics will be performed for participant
characteristics as well as baseline testosterone, strength,
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exists between the randomized groups. If bias does exist,
these variables will be included as covariates in the
primary analysis. The raw data (pre- and post-test) will be
plotted to determine if outliers exist. Because the sample
size is small if outliers are found, transformations of the
data (e.g. log transformation) will be attempted. If this is
not feasible, results will be compared using non-parametric
analogs to the parametric tests listed below. Intent to treat
analyses for specific hypotheses are listed below. In
addition, effect sizes will be computed with Cohen’s D to
determine the clinical relevance of the results and assist in
powering further research. Analyses will be performed
using SPSS for all analyses with α = 0.05. If there is any
missing data, the analyses can be performed with the SPSS
multiple imputation procedure.
Intent to treat will be tested by comparing changes in
lean mass and strength using ANCOVA models, with
group adjusting for baseline values. KOOS and TAS
scores will be analyzed by ANCOVA models. Physical
function tests scores on the Lachman and pivot shift
tests will be analyzed by χ2 test. The changes in gene ex-
pression of Akt1, mTOR, and FOXO3a will be compared
by ANCOVA models.
Power analysis
Sample size estimates were computed with Nquery (v4)
for α = 0.05 and 1-β = 0.80. Preliminary data was taken
from a study that provided 12 weeks of oxandrolone/day
in 32 healthy 60–87 year old men [24]. Effects sizes
between changes in means from baseline to 12 weeks for
lean body mass and maximal voluntary strength were
used to estimate the changes in mass and strength for
Aim 1. The effect size was 2.0 for mass and 2.03 for
strength. For similar effects, a minimum of 6 men would
be needed for each group. Assuming a 20% attrition rate
[1] and similarly very large effect, our sample of 7 per
group should be sufficient to see statistically significant
effects.
Discussion
In this study, we are testing the hypothesis that standard-
of-care rehabilitation with the addition of supraphysiologic
doses of testosterone for 8 weeks will augment muscle
mass, strength, and physical function following ACL re-
constructive surgery compared to standard rehabilitation
alone.
Use of testosterone
Testosterone is the principal male sex hormone and an
anabolic steroid. It is essential for healthy males. In men,
testosterone plays a key role in the development of male
reproductive tissues and promotes secondary sexual
characteristics such as increased muscle, bone mass, andthe growth of body hair. In young healthy male subjects
similar to those used in our study, supraphysiologic
doses of testosterone have been shown to increase fat-free
mass, muscle size and strength independent of exercise
[4]. This effect was even greater when testosterone was
used in conjunction with strength training. Additionally,
testosterone likely causes some of its effects, such as
muscle strength, in a dose dependent manner [38].
While few studies have used supraphysiologic doses of
testosterone, the ideal dosing for adjunctive therapy with
ACL surgery is not known. Because our patients will not
necessarily be hypogonadal, as is typical for testosterone
replacement studies, there is a risk that our dose may
not be large enough to have a significant influence on
muscle mass and strength. Alternatively, a dose that is
too high (>600 mg/wk) [38] or given for long duration
(6 months) [39] may have deleterious effects by increas-
ing risk of cardiovascular disease. However, we believe
that our chosen dose regimen will be safe and successful
as it is based on the current literature and the expertise
of our study team [5,13].
The potential detrimental cardiovascular side effects of
testosterone have recently been featured in both the
literature and the media [40]. However, these studies
focus primarily on testosterone replacement therapy for
an extended duration and are mainly in hypogonadal
men and therefore are not as applicable to our current
study. We do not anticipate any negative side effects of
the testosterone treatment, but will be monitoring all
patients closely for any potential complications.
Study participants
In our study, we will use young healthy males aged 18–50
with recent acute ACL tears. This demographic will be
used in an attempt to isolate the effect of testosterone and
minimize any confounding factors such as age, comorbidi-
ties and sex. Women will not be used in this initial study
due to the gender related side effects of testosterone. Add-
itionally, the results showing the ability of supraphysiologic
doses of testosterone to augment muscle size and strength
were reported for young healthy males [38]. However, we
do not believe that the benefits of testosterone on rehabili-
tation are isolated to this demographic alone. If this study
shows significant results, the next step would be to expand
our age range and conduct studies with other atrophy-
related surgeries such as total knee arthoplasty.
Limitations
Testosterone therapy is currently a controversial topic but
previous studies have shown positive results [8,41-48]. It
may have been ideal to personalize the supraphysiologic
doses according to baseline for each participant. However,
for ease of administration and future research viability, we
attempted to standardize this value. It may be interesting
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results for those participants. Similarly, there is a large age
range of participants and studies have shown differences in
testosterone level as early as 40 years of age [44,48-52].
However, additional studies show that the effects in males
will still exist with supraphysiologic doses [48,53,54] and we
expect an effect to be measured independent of age or race.
Recruitment of participants who meet all inclusion
criteria will be challenging. Although we are working with
multiple orthopedic surgeons, there are a number of
challenges in recruiting patients with ACL injury into
randomized clinical trials [55]. It will likely be necessary to
recruit and screen approximately 70 participants – 5 times
as many potential participants as our power analysis indi-
cates to demonstrate significant differences.
Additionally, while we aim to work with as few physical
therapists as possible and are following a standardized
protocol, there are differences in the techniques and
progression of individual therapists. We intend to monitor
progress of individual participants as standardized as
possible and to also focus on the 24 week result as the
primary outcome time point.
Relevance for investigating the effects of testosterone on
rehabilitation
The present study will contribute to the field of rehabilita-
tion following invasive surgery with respect to under-
standing an innovative approach towards treating injury
induced muscle atrophy. By examining the effects of tes-
tosterone following surgery as an adjunct therapy, we can
observe the effects on multiple translational levels includ-
ing clinical outcomes, quality of life, and mechanisms.
The results of the study will help provide the framework
for additional large scale and multi-centered investigations
to optimize rehabilitation in surgeries that affect many
persons and injuries.
Because many patients do not return to pre-surgical
levels of activity and strength [1,29,56], continued research
is necessary to study muscle atrophy, a critical component
of this poor return. Furthermore, these effects are often
compounded in elite athletes [28,57] and although this
present study does not focus on these patients, they are a
crucial group that may benefit from such research. Ideally,
such methods for targeting muscle atrophy should be
applicable across gender, age, and injury type. Future and
vigorous research will be required to test such hypotheses,
as testosterone levels play a critical role in overall health.
Testosterone has never been studied in the age range of
our patients for therapy following injuries associated with
muscle atrophy. We believe that testosterone will improve
the outcome of ACL reconstruction and augment muscle
mass, strength, and physical function compared to
standard-of-care alone. If our study demonstrates that
acute testosterone improves rehabilitation following ACLreconstruction, it may be possible to apply the same con-
cept to other injuries that involve muscle atrophy. With
almost every orthopedic injury and accompanying surgery,
there is a disuse muscle atrophy that occurs that will
ultimately lengthen the period of rehabilitation needed to
get back to full strength [6]. We believe that testosterone
therapy will help prevent this loss of muscle mass and can
shorten the length of rehabilitation needed in these pa-
tients. In addition, by analyzing muscle tissue following an
ACL rupture with or without testosterone administration,
we can learn more about the mechanism through which
muscle adapts to trauma and how testosterone affects this
process. Therefore, we may learn more about testoster-
one’s mechanism of action in skeletal muscle during the
catabolic stimulus of bedrest and surgery.
A unique aspect of our proposed adjunct therapy to
ACL reconstruction is its clinical feasibility. Testosterone
therapy is easily added to the standard-of-care rehabilita-
tion with little additional time or effort required by the
patient. The testosterone injections can be administered at
routine preoperative and postoperative visits, with few
extra office visits necessary. This would allow many add-
itional patients to have access to the therapy regardless of
time constraints.
Conclusion
This study will contribute to the understanding of skeletal
muscle adaptations to trauma and surgery, and how testos-
terone can affect this process. We believe that testosterone
will augment muscle mass and improve rehabilitation
times following ACL reconstructive surgery and quality of
life for patients with this injury. In the future, we hope that
the principles of testosterone therapy following injury and
disuse atrophy can be expanded to a larger cohort of
patients and a more diverse range of injuries and surgeries.
The results from this study will allow for larger scale stud-
ies investigating the optimization of testosterone therapy in
rehabilitation for various types of injuries.
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